tetano
Editor, Senior Moderator
Sci Rep
. 2021 Nov 12;11(1):22164.
doi: 10.1038/s41598-021-01780-8.
Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1
Raveen Rathnasinghe[SUP] 1 2 3 [/SUP], Mirella Salvatore[SUP] 4 [/SUP], Hongyong Zheng[SUP] 1 [/SUP], Sonia Jangra[SUP] 1 3 [/SUP], Thomas Kehrer[SUP] 1 2 3 [/SUP], Ignacio Mena[SUP] 1 3 [/SUP], Michael Schotsaert[SUP] 1 3 [/SUP], Thomas Muster[SUP] 5 [/SUP], Peter Palese[SUP] 1 6 [/SUP], Adolfo García-Sastre[SUP] 7 8 9 10 [/SUP]
Affiliations
Abstract
The influenza A non-structural protein 1 (NS1) is known for its ability to hinder the synthesis of type I interferon (IFN) during viral infection. Influenza viruses lacking NS1 (ΔNS1) are under clinical development as live attenuated human influenza virus vaccines and induce potent influenza virus-specific humoral and cellular adaptive immune responses. Attenuation of ΔNS1 influenza viruses is due to their high IFN inducing properties, that limit their replication in vivo. This study demonstrates that pre-treatment with a ΔNS1 virus results in an antiviral state which prevents subsequent replication of homologous and heterologous viruses, preventing disease from virus respiratory pathogens, including SARS-CoV-2. Our studies suggest that ΔNS1 influenza viruses could be used for the prophylaxis of influenza, SARS-CoV-2 and other human respiratory viral infections, and that an influenza virus vaccine based on ΔNS1 live attenuated viruses would confer broad protection against influenza virus infection from the moment of administration, first by non-specific innate immune induction, followed by specific adaptive immunity.
. 2021 Nov 12;11(1):22164.
doi: 10.1038/s41598-021-01780-8.
Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1
Raveen Rathnasinghe[SUP] 1 2 3 [/SUP], Mirella Salvatore[SUP] 4 [/SUP], Hongyong Zheng[SUP] 1 [/SUP], Sonia Jangra[SUP] 1 3 [/SUP], Thomas Kehrer[SUP] 1 2 3 [/SUP], Ignacio Mena[SUP] 1 3 [/SUP], Michael Schotsaert[SUP] 1 3 [/SUP], Thomas Muster[SUP] 5 [/SUP], Peter Palese[SUP] 1 6 [/SUP], Adolfo García-Sastre[SUP] 7 8 9 10 [/SUP]
Affiliations
- PMID: 34773048
- DOI: 10.1038/s41598-021-01780-8
Abstract
The influenza A non-structural protein 1 (NS1) is known for its ability to hinder the synthesis of type I interferon (IFN) during viral infection. Influenza viruses lacking NS1 (ΔNS1) are under clinical development as live attenuated human influenza virus vaccines and induce potent influenza virus-specific humoral and cellular adaptive immune responses. Attenuation of ΔNS1 influenza viruses is due to their high IFN inducing properties, that limit their replication in vivo. This study demonstrates that pre-treatment with a ΔNS1 virus results in an antiviral state which prevents subsequent replication of homologous and heterologous viruses, preventing disease from virus respiratory pathogens, including SARS-CoV-2. Our studies suggest that ΔNS1 influenza viruses could be used for the prophylaxis of influenza, SARS-CoV-2 and other human respiratory viral infections, and that an influenza virus vaccine based on ΔNS1 live attenuated viruses would confer broad protection against influenza virus infection from the moment of administration, first by non-specific innate immune induction, followed by specific adaptive immunity.